Clinical Trial Stage
The Clinical Trial Stage grant from the California Institute for Regenerative Medicine funds advanced clinical trials of stem cell and genetic therapies for serious diseases with unmet medical needs.
Funder: California Institute for Regenerative Medicine
Due Dates: June 30, 2025 | October 31, 2025 | October 30, 2026
Funding Amounts: $8M–$15M total costs per award; up to 4 years; co-funding required for some applicants/trial phases
Summary: Supports clinical trials of stem cell-based and genetic therapies for diseases with significant unmet needs, advancing candidates toward marketing approval and patient access.
Key Information: Quarterly deadlines; eligibility for both California and non-California for-profit and non-profit organizations; co-funding and California site required for some applicants.
Description
This program funds interventional phase 1, 2, or 3 clinical trials (including pivotal trials) for innovative stem cell-based or genetic therapies targeting serious diseases with unmet medical needs. The initiative aims to accelerate clinical development, facilitate regulatory approval, and ensure patient access to transformative therapies. Supported activities include clinical operations, patient outreach and enrollment, manufacturing, regulatory work, biomarker studies, and access planning. Emphasis is placed on trial demographics that reflect the affected patient population and on strategies for pre-commercialization and affordability.
